The Company
Our Journey
Our Journey
We face some of the most difficult challenges in genomic research for mental disorders. This demands innovation. At Systasy, we have a new visionary and creative approach to research that pushes the boundaries of our understanding in ever new and exciting ways.
Establishment of a multiparametric safety profiling assay to assess target selectivity and physiological pathway effects of neuroleptics in living cells
Profiling in iPSCs
Establishment of a profiling tool for induced pluripotent stem cells (IPSCs) and cell types differentiated thereof
Zim Grant
Establishment of a GPCR screening tool for inverse agonists and testing of a compound toolbox. Collaboration with University of Jena, Institute for Organic Chemstry and Macromolecular Chemistry, providing novel compounds.
First coumpound screen that used the splitSENSOR technology published
SplitSENSOR-based screening of repurposed drugs identified spironolactone as antagonist of ERBB4, a schizophrenia risk gene. In a mouse model of schizophrenia, spironolactone improved relevant endophenotypes in these mice, sparking the initiation of clinical study to assess effectiveness of spironolactone in schizophrenic patients.
Partners in European Marie Curie ITN Network – PDZnet Development of genetic screening tools assessing PDZ protein function in neuronal signalling pathways and PDZ protein interactions to explore therapeutic potential.
Licensing of Systasy’s splitSENSOR patent to Boehringer Ingelheim Systasy Bioscience announces non-exclusive licence agreement with Boehringer Ingelheim forsplitSENSOR assays.
Development of a GPCR profiling tool.
The tool monitors GPCR activities by combining splitSENSOR assays and molecular barcodes as readouts
First products and services sold
Establishment and transfer of an ERBB4 acitvity assay to screen a large compound library for ERBB4 modulators.
Founded in Munich in July 2012 as spin OFF from the Max Planck Institute of Experimental Medicine, Göttingen.
Funding for promoting concepts and products/services to establish Systasy Bioscience GmbH.
BMBF awarded the Validierungs-förderung VIP+ Grant to the laboratory of the Founder Prof. Moritz Rossner for the development of EXTassay – an EXT-based technology platform for highly-parallel drug analysis
This site collects cookies and if you continue to use this website, you consent to use of our cookies.
OKLearn MoreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy